First-in-class, disease-modifying, once-a-year infusion for osteoarthritis

This Pennsylvania-based company’s asset disrupts current treatment of osteoarthritis

  • Once per year intravenous infusion
  • Controls pain
  • Increases joint function
  • Modifies the disease by reducing bone marrow lesions across multiple joints

Seeking investment of $25M-$30M to reach market (Full FDA approval), or Partnership to co-develop or license asset for specific application. Suitable for both human and animal health.

  • Disease modification shown in human trial (Phase III)
  • Relieves pain, increases joint mobility
  • Applicable for multiple joints
  • Once a year IV administration (as opposed to IA)
  • Reformulation of approved compounds of known safety
  • Zoledronic acid (ZA) + methylprednisolone (MP)
  • Strong patent position through 2033 – 3 US and 4 International patents awarded thus far